Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Application History
34 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 12, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 3, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 31, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 27, 2023 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Oct 27, 2023 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 27, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 20, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 18, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 18, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 3, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 1, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 1, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 1, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 29, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 27, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 27, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 27, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 2, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 22, 2021 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Aug 11, 2021 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Jul 13, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 13, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 23, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 4, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 3, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 3, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 3, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 31, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 31, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 31, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 29, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 23, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 18, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Classification
International Classes
005